Advertisement

Drugs

, Volume 73, Issue 18, pp 2077–2091 | Cite as

Abiraterone Acetate: A Review of Its Use in Patients with Metastatic Castration-Resistant Prostate Cancer

  • Sheridan M. Hoy
Adis Drug Evaluation

Abstract

Abiraterone acetate (Zytiga®) is an orally administered, selective inhibitor of the 17α-hydroxylase and C17,20-lyase enzymatic activities of cytochrome P450 (CYP) 17. CYP17 is required for androgen biosynthesis, with androgen receptor signalling crucial in the progression from primary to metastatic prostate cancer. Abiraterone acetate is approved in the European Union and the US, in combination with prednisone or prednisolone, for the treatment of men with metastatic castration-resistant prostate cancer (CRPC). When administered in combination with prednisone in a placebo-controlled, multinational phase III study, abiraterone acetate significantly prolonged overall survival and radiographic progression-free survival (rPFS) in men with metastatic CRPC who had previously received docetaxel. In men with metastatic CRPC who had not previously received chemotherapy participating in a placebo-controlled, multinational phase III study, there was a strong trend towards an overall survival benefit, a significant prolongation in rPFS and significant delays in clinical decline, the need for chemotherapy and the onset of pain observed. Given the nature of the therapy, the overall tolerability profile of abiraterone acetate, in combination with prednisone, was acceptable in men with metastatic CRPC. Abiraterone acetate is associated with hypokalaemia, hypertension, and fluid retention or oedema, secondary to its mechanism of action, and with cardiac adverse events and hepatotoxicity; however, in the phase III studies the incidences of the most frequently reported grade 3 or 4 adverse events of special interest were relatively low. Although the final overall survival data in men with metastatic CRPC who have not previously received chemotherapy are awaited, current evidence indicates that abiraterone acetate is a useful option for the treatment of metastatic CRPC.

Keywords

Docetaxel Androgen Receptor DHEA Androgen Deprivation Therapy National Comprehensive Cancer Network 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

References

  1. 1.
    Bluemn EG, Nelson PS. The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol. 2012;24(3):251–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Massard C, Fizazi K. Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res. 2011;17(12):3876–83.PubMedCrossRefGoogle Scholar
  3. 3.
    Horwich A, Parker C, Bangma C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v129–33.PubMedCrossRefGoogle Scholar
  4. 4.
    Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(Suppl 2):S72–9.PubMedGoogle Scholar
  5. 5.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer (Version 4.2013). 2013. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (Accessed 11 Nov 2013).
  6. 6.
    Mohler JL, Titus MA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res. 2011;17(18):5844–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Schweizer MT, Antonarakis ES. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol. 2012;4(4):167–78.PubMedCrossRefGoogle Scholar
  8. 8.
    Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22(6):1025–33.PubMedCrossRefGoogle Scholar
  9. 9.
    Attard G, Reid AH, A’Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27(23):3742–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Tsao CK, Galsky MD, Small AC, et al. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int. 2012;110(11):1580–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Yang LP. Abiraterone acetate: in metastatic castration-resistant prostate cancer [Erratum appears in Drugs. 2012;72(2):192]. Drugs. 2011;71(15):2067–77.PubMedCrossRefGoogle Scholar
  12. 12.
    European Medicines Agency. ZYTIGA 250 mg tablets: summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002321/WC500112858.pdf (Accessed 11 Nov 2013).
  13. 13.
    Janssen Biotech Inc. ZYTIGA® (abiraterone acetate) tablets: prescribing information; 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202379s007lbl.pdf (Accessed 11 Nov 2013).
  14. 14.
    Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54.PubMedCrossRefGoogle Scholar
  15. 15.
    Li R, Evaul K, Sharma KK, et al. Abiraterone inhibits 3-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012;18(13):3571–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Potter GA, Barrie SE, Jarman M, et al. Novel steroidal inhibitors of human cytochrome P45017α (17α-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem. 1995;38(13):2463–71.PubMedCrossRefGoogle Scholar
  17. 17.
    Yamaoka M, Hara T, Kusaka M. Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin Cancer Res. 2010;16(17):4319–24.PubMedCrossRefGoogle Scholar
  18. 18.
    Ang JE, Olmos D, de Bono JS. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer. 2009;100(5):671–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [Erratum appears in J Clin Oncol. 2012;30(15):1896]. J Clin Oncol. 2008;26(28):4563–71.PubMedCrossRefGoogle Scholar
  20. 20.
    Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28(9):1481–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Efstathiou E, Titus M, Tsavachidou D, et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol. 2012;30(6):637–43.PubMedCrossRefGoogle Scholar
  22. 22.
    Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28(9):1489–95.PubMedCrossRefGoogle Scholar
  23. 23.
    Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010;28(9):1496–501.PubMedCrossRefGoogle Scholar
  24. 24.
    Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–48.PubMedCrossRefGoogle Scholar
  25. 25.
    de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.PubMedCrossRefGoogle Scholar
  26. 26.
    Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983–92.PubMedCrossRefGoogle Scholar
  27. 27.
    Cai C, Balk SP. Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. Endocr Relat Cancer. 2011;18(5):R175–82.PubMedCrossRefGoogle Scholar
  28. 28.
    Attard G, Reid AH, Olmos D, et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 2009;69(12):4937–40.PubMedCrossRefGoogle Scholar
  29. 29.
    Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71(20):6503–13.PubMedCrossRefGoogle Scholar
  30. 30.
    Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17(18):5913–25.PubMedCrossRefGoogle Scholar
  31. 31.
    van Soest RJ, van Royen ME, de Morrée ES, et al. Effects on androgen receptor nuclear import by docetaxel, cabazitaxel, abiraterone, and enzalutamide: potential mechanism for cross-resistance in castration-resistant prostate cancer (CRPC) [abstract no. 5064]. J Clin Oncol. 2013;31(15 Suppl 1).Google Scholar
  32. 32.
    Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011;17(14):4854–61.PubMedCrossRefGoogle Scholar
  33. 33.
    Tolcher AW, Chi KN, Shore ND, et al. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2012;70(2):305–13.PubMedCrossRefGoogle Scholar
  34. 34.
    Marbury T, Stonerock R, Acharya M, et al. A phase 1 single-dose open-label pharmacokinetic (PK) study of abiraterone acetate (AA) in male subjects with mild or moderate hepatic impairment [abstract no. 7055]. Eur J Cancer. 2011;47:S501.CrossRefGoogle Scholar
  35. 35.
    Marbury T, Stonerock R, Tran N, et al. A phase 1 single dose open-label reduced/staged pharmacokinetic (PK) and safety study of abiraterone acetate (AA) in men with impaired renal function [abstract no. 7057]. Eur J Cancer. 2011;47:S502.CrossRefGoogle Scholar
  36. 36.
    Chi KN, Tolcher A, Lee P, et al. Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2013;71(1):237–44.PubMedCrossRefGoogle Scholar
  37. 37.
    Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13(12):1210–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Sternberg CN, Molina A, North S, et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol. 2013;24(4):1017–25.PubMedCrossRefGoogle Scholar
  39. 39.
    Harland S, Staffurth J, Molina A, et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 2013;49(17):3648–57.Google Scholar
  40. 40.
    Saad F, Shore ND, Van Poppel H, et al. Abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy: interim analysis of the COU-AA-302 phase 3 trial [abstract no. 713]. J Urol. 2013;189(4 Suppl):e293.Google Scholar
  41. 41.
    Shore N, Ryan CJ, Mulders P, et al. The impact of abiraterone acetate therapy on patient-reported pain and functional status in chemotherapy-naïve patients with progressive, metastatic castration-resistant prostate cancer: results from an updated analysis [abstract no. 784]. J Urol. 2013;189(4 Suppl):e323.Google Scholar
  42. 42.
    Scher HI, Heller G, Molina A, et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel [abstract no. LBA4517]. J Clin Oncol. 2011;29(18 Suppl 2).Google Scholar
  43. 43.
    Goodman OB, Flaig TW, Molina A, et al. Exploratory analysis of the visceral disease (VD) patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) [abstract no. 14]. J Clin Oncol. 2013;31(Suppl 6).Google Scholar
  44. 44.
    European Medicines Agency. Assessment report: Zytiga (abiraterone); 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/002321/WC500137814.pdf (Accessed 11 Nov 2013).
  45. 45.
    Rathkopf DE, Smith MR, de Bono JS, et al. Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302) [abstract no. 5009]. J Clin Oncol. 2013;31(15 Suppl 1).Google Scholar
  46. 46.
    Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer; 2011. http://www.uroweb.org/gls/pdf/08_Prostate_Cancer.pdf (Accessed 11 Nov 2013).
  47. 47.
    European Medicines Agency. Xtandi 40 mg soft capsules: summary of product characteristics; 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002639/WC500144996.pdf (Accessed 11 Nov 2013).
  48. 48.
    Astellas Pharma US Inc. XTANDI® (enzalutamide) capsules for oral use: prescribing information; 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf (Accessed 11 Nov 2013).
  49. 49.
    Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.PubMedCrossRefGoogle Scholar
  50. 50.
    Rescigno P, Buonerba C, Bellmunt J, et al. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets. 2012;13(13):1676–86.PubMedCrossRefGoogle Scholar
  51. 51.
    Plosker GL. Sipuleucel-T: in metastatic castration-resistant prostate cancer. Drugs. 2011;71(1):101–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59(4):572–83.PubMedCrossRefGoogle Scholar
  53. 53.
    McKeage K. Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer. Drugs. 2012;72(11):1559–77.PubMedCrossRefGoogle Scholar
  54. 54.
    Keating GM. Cabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancer. Drugs Aging. 2013;30(5):359–65.PubMedCrossRefGoogle Scholar
  55. 55.
    National Institute for Health and Clinical Excellence. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (NICE technology appraisal guidance 259); 2012. http://guidance.nice.org.uk/TA259/Guidance/pdf/English (Accessed 11 Nov 2013).
  56. 56.
    Pereira ML, Bahmdouni LS, Pepe C, et al. Cost-effectiveness analysis of abiraterone for the treatment of advanced prostate cancer under the Brazilian private health care system [abstract no. PCN86]. Value Health. 2012;15(7):A424–5.CrossRefGoogle Scholar
  57. 57.
    Persson U, Nilsson S, Hjortsberg C, et al. Economic evaluation of abiraterone acetate as treatment for metastatic castration resistant prostate cancer after failure of docetaxel in Sweden [abstract no. PCN66]. Value Health. 2012;15(4):A219.CrossRefGoogle Scholar
  58. 58.
    Wilson LS, Zhong L, Pon V, et al. Cost effectiveness analysis of new treatments for metastatic castration-resistant prostate cancer: does severity matter? [abstract no. PCN72]. Value Health. 2012;15(4):A220–1.CrossRefGoogle Scholar
  59. 59.
    Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148–59.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisNorth ShoreNew Zealand

Personalised recommendations